

## Recent patent applications in protein expression

Patent #	Subject	Assignee(s)	Inventor(s)	Priority	
				application date	Publication date
US 20060216760, WO 2006069203	A method for determining protein expression patterns in a cell or a tissue, comprising contacting the cell or the tissue with a nonnatural amino acid comprising a first reactive group under a condition where the nonnatural amino acid is incorporated into the newly synthesized proteins of the cell or the tissue.	California Institute of Technology (Pasadena, CA, USA)	Dieterich DC, Link AJ, Schuman E, Tirrell DA, Tirrell D	12/22/2004	9/28/2006, 6/29/2006
JP 2006230251	A fusion protein expression vector, comprising a restriction enzyme site for inserting the gene encoding a protein derived from <i>Halobacterium</i> and a gene encoding a target protein downstream of the <i>Halobacterium</i> gene and a protease cleavage site, where the target protein is expressed as a fusion protein along with the protein derived from <i>Halobacterium</i> ; enables efficient expression and synthesis of slightly soluble protein.	Kagoshima University (Kagoshima, Japan)	Ishibashi M, Tokunaga H, Tokunaga M	2/23/2005	9/7/2006
EP 1698702	A polynucleotide comprising an expressible sequence and a promoter sequence that is useful for manufacturing a pharmaceutical composition.	Gellissen G	Gellissen G	3/2/2005	9/6/2006
US 20060194284, WO 2006089613	A host organism containing a vitamin K reductase complex subunit 1 (VKORC1) and a vitamin K-dependent (VKD) protein; useful for the study of the improvement in the productivity of recombinant VKD protein expression.	Baxter Healthcare SA (Wallisellen, Switzerland), Baxter International (Deerfield, IL, USA)	Boehm E, Scheiflinger F	2/28/2005	8/31/2006
WO 2006091483	A phage-derived vector comprising one or more factors that direct expression of a polypeptide of interest and at least one conditional promoter operably linked to coding sequences expressing one or more late phage transcripts; useful for cloning or expressing a heterologous polypeptide of interest in a bacterial cell.	Tabaczynski D	Tabaczynski D	2/22/2005	8/31/2006
WO 2006073976	A nucleic acid composition for enhancing expression levels or solubility of a protein of interest, comprising an isolated nucleic acid encoding SUMO protein, the protein of interest, and one or more purification tags.	LifeSensors Inc. (Malvern, PA, USA)	Butt T, Sterner D, Zuo X	12/30/2004	7/13/2006
US 20060134743	A vankyrin expression vector comprising a nucleic acid encoding the polypeptide comprising a sequence of 171 amino acids or comprising a nucleic acid comprising a sequence of 513 base pairs; useful for enhancing target protein production of a cell line producing a target protein.	Koemer J, Webb BA	Koemer J, Webb BA	12/21/2004	6/22/2006
WO 2004081033, US 20060134739	An <i>in vitro</i> protein or biological macromolecule synthesis system comprising one or more energy sources providing chemical energy for protein or biological macromolecule synthesis, where at least one of the energy sources is a glycolytic intermediate or a tricarboxylic acid cycle intermediate.	US National Institutes of Health (Rockville, MD, USA), Chatterjee DK	Chatterjee DK	9/9/2005	9/23/2004, 6/22/2006
US 20060105953	A polynucleotide encoding a protease-regulated polypeptide, comprising a protein degradation signal, a polypeptide of interest and a linker; useful for detecting, examining and exploiting protease-mediated protein expression.	Regents of the University of California (Oakland, CA, USA)	Evans CJ, Lacoste A	11/17/2004	5/18/2006
US 7041801	An isolated, purified antibody that binds to a polypeptide of a mammalian Del-1, where the mammalian Del-1 comprises an amino acid sequence of 480, 221, 481 or 180 amino acids; useful as an endothelial cell and tumor marker, and for immunological assessment of Del-1 protein expression.	Vanderbilt University (Nashville, TN, USA), Valentis (Burlingame, CA, USA)	Hogan B, Quertermous T, Snodgrass HR, Zupancic TJ	6/5/1996	5/9/2006
WO 2006042979, FR 2877014	A transitory expression system of recombinant proteins in a plant for the pharmaceutical production of proteins, comprising a viral expression vector comprising a ubiquitous constitutive promoter.	Institut de Recherche pour le Développement (Paris)	Brugidou C, Lemesre J, Lemesre JL, Piron F, Reyser M, Sire C	10/21/2004	4/27/2006, 4/28/2006

Source: Thomson Scientific Search Service (formerly Derwent). The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1725 Duke Street, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) DERWENT (<http://www.thomson.com/scientific>).